News
Multiple Sclerosis
New drug shows promise in promoting MS recovery
Multiple sclerosis (MS) is a neurodegenerative disease characterised by chronic infla...
Scope 66 - Why do some people respond better to MS treatment...
A recent exploratory trial looking at the effect of the drug MIS416 on patients has f...
Scope 65 - Great New Zealand Trek 2018: Stage 13 completed
More than 400 participants and support crew descended on the picturesque Central ...
Scope 64 - Research in focus: Multiple Sclerosis
The Multiple Sclerosis team has been working with a New Zealand biomedical company...
Scope 63 - Optimizing the use of antipsychotic medicines for...
Professor Anne La Flamme and her Multiple Sclerosis (MS) research group recently publ...
The Great New Zealand Trek: 9 Years and more than NZ$250,000...
With an impressive 238 participants taking part this year, it’s been another successf...
The Great New Zealand Trek has raised almost a quarter of a ...
Over the last 8 years, The Great New Zealand Trek has donated $245,000 to help find a...
Research Report 2016 - Multiple sclerosis
A Phase Ib/IIa suitability and acceptability trial of two antipsychotic medicines, cl...
Funding brings Multiple Sclerosis clinical trial closer
The journey to deliver a new (and first-ever) treatment for secondary progressive MS ...
MS drug research featured on ONE News
On Thursday night, 14 August 2014, Dr Anne La Flamme's latest Multiple Sclerosis rese...